Golden
Exopharm

Exopharm

Exopharm is a regenerative medicine biopharmaceutical company spun out of Altnia Group. Founded in 2003 and based in Melbourne, Australia, the company aims to develop and commercialize exosomes as therapeutic agents.

All edits

Edits on 14 Mar 2020
Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 14 Mar 2020 2:44 pm
Edits made to:
Article (+15/-15 characters)

Article

Exopharm's proprietary LEAP TechnologyLEAP Technology provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells and other sources which claims to address existing limitations in exosome purification processes. Exopharm's technology is designed for the manufacture of a proprietary exosome product at clinical and then pharmaceutical grade and scale.

Edits on 23 Feb 2020
Golden AI"Adding location topic from lookup Melbourne, Victoria"
Golden AI edited on 23 Feb 2020 6:27 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 22 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 22 Mar 2019 1:12 pm
Edits made to:
Article (+10/-10 characters)

Article

Exopharm's products include Plexaris, exosomes derived from human platelets, and Exomeres, exosomes from stem cellsstem cells.Exosomes are extracellular vesicles involved in cell-cell communication and transmission of disease states through transfer of protein, RNA, lipids and microRNA. Exosomes are thought to mediate some of the regenerative effects of stem cells and provide a cell-free therapeutic agent with therapeutic benefits.The company aims to treat diseases such as dry Age Related Macular Degeneration (AMD), tendinopathy, arthritis, cardiac repair, neurodegeneration and aging.

Edits on 14 Mar 2019
Dawson Sewell
Dawson Sewell edited on 14 Mar 2019 4:20 pm
Edits made to:
Infobox (+9 properties)
Article (+1 videos) (+26 characters)
Further reading (+3 rows) (+12 cells) (+428 characters)
Documentaries, videos and podcasts (+1 rows) (+3 cells) (+85 characters)

Article



Further reading

Title
Author
Link
Type

Exopharm company spun out to commercialise a completely new type of nano-drug for regenerative medicine

Medianet

Web

Stem Cell Exomere Program announced by RoosterBio and Exopharm

Prweb

Web

Documentaries, videos and podcasts

Title
Date
Link

Exopharm CA MIX2 20181019

December 27, 2018

Infobox

Edits on 20 Feb 2019
Melanie Manipula
Melanie Manipula approved a suggestion from Golden's AI on 20 Feb 2019 9:45 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 1 Feb 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 1 Feb 2019 7:14 pm
Edits made to:
Article (+21/-21 characters)

Article

The Stem Cell Exomere Program is a partnership between RoosterBio and Exopharm to develop and implement a standardized, scalable, commercially-viable biomanufacturing process and a cGMP-compliant Exomere product (exosomes) for regenerative medicineregenerative medicine applications.

Edits on 30 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 30 Jan 2019 7:10 am
Edits made to:
Article (+3/-3 characters)

Article

Exopharm's products include Plexaris, exosomes derived from human platelets, and Exomeres, exosomes from stem cells.Exosomes are extracellular vesicles involved in cell-cell communication and transmission of disease states through transfer of protein, RNARNA, lipids and microRNA. Exosomes are thought to mediate some of the regenerative effects of stem cells and provide a cell-free therapeutic agent with therapeutic benefits.The company aims to treat diseases such as dry Age Related Macular Degeneration (AMD), tendinopathy, arthritis, cardiac repair, neurodegeneration and aging.

Meredith Hanel
Meredith Hanel edited on 30 Jan 2019 2:30 am
Edits made to:
Article (+262 characters)
Related Topics (+1 topics)

Article



The Stem Cell Exomere Program is a partnership between RoosterBio and Exopharm to develop and implement a standardized, scalable, commercially-viable biomanufacturing process and a cGMP-compliant Exomere product (exosomes) for regenerative medicine applications.

Related Topics

Meredith Hanel
Meredith Hanel edited on 30 Jan 2019 2:20 am
Edits made to:
Article (+35 characters)

Article

Exopharm's products include Plexaris, exosomes derived from human platelets, and Exomeres, exosomes from stem cells.Exosomes are extracellular vesicles involved in cell-cell communication and transmission of disease states through transfer of protein, RNA, lipids and microRNA. Exosomes are thought to mediate some of the regenerative effects of stem cells and provide a cell-free therapeutic agent with therapeutic benefits.The company aims to treat diseases such as dry Age Related Macular Degeneration (AMD), tendinopathy, arthritis, cardiac repair, neurodegeneration and aging.

Meredith Hanel
Meredith Hanel edited on 30 Jan 2019 2:19 am
Edits made to:
Article (+22/-12 characters)

Article

Exopharm's proprietary LEAP Technology provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells and other sources andwhich addressesclaims to address existing limitations in exosome purification processes. Exopharm's technology is designed for the manufacture of a proprietary exosome product at clinical and then pharmaceutical grade and scale.

Meredith Hanel
Meredith Hanel edited on 30 Jan 2019 2:17 am
Edits made to:
Infobox (+3 properties)
Description (+216 characters)
Article (+925 characters)
People (+4 rows) (+8 cells) (+231 characters)
Categories (+2 topics)
Related Topics (+1 topics)
Topic thumbnail

Exopharm

Exopharm is a regenerative medicine biopharmaceutical company spun out of Altnia Group. Founded in 2003 and based in Melbourne, Australia, the company aims to develop and commercialize exosomes as therapeutic agents.

Article

Exopharm's products include Plexaris, exosomes derived from human platelets, and Exomeres, exosomes from stem cells.Exosomes are extracellular vesicles involved in cell-cell communication and transmission of disease states through transfer of protein, RNA, lipids and microRNA. Exosomes are thought to mediate some of the regenerative effects of stem cells and provide a cell-free therapeutic agent with therapeutic benefits.The company aims to treat diseases such as dry AMD, tendinopathy, arthritis, cardiac repair, neurodegeneration and aging.



Exopharm's proprietary LEAP Technology provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells and other sources and addresses existing limitations in exosome purification processes. Exopharm's technology is designed for the manufacture of a proprietary exosome product at clinical and then pharmaceutical grade and scale.















People

Name
Role
Related Golden topics

David Parker

Non-Executive Director



Gregor Lichtfuss, MSc, DTMPH

Technology Co-Founder and Chief Operating Officer



Ian Dixon, PhD, MBA, MAICD

Company Founder, Technology Co-Founder and Managing Director



Jason Watson

Non-Executive Chairman



Infobox

Categories

Related Topics

Edits on 29 Jan 2019
Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 29 Jan 2019 3:38 am
Edits made to:
Topic thumbnail

 Exopharm

Exopharm is a regenerative medicine biopharmaceutical company spun out of Altnia Group. Founded in 2003 and based in Melbourne, Australia, the company aims to develop and commercialize exosomes as therapeutic agents.

No more activity to show.